An Open-label, Phase 1, Single-dose Study to Evaluate the Pharmacokinetics of Elafibranor 120 mg in Adult Subjects With Hepatic Impairment and Adult Healthy Control Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Elafibranor (Primary)
- Indications Liver disorders; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Genfit
- 21 Aug 2019 Status changed from recruiting to completed.
- 24 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Dec 2018 New trial record